German G-BA positive on Eisai's Halaven despite IQWiG's concerns
This article was originally published in Scrip
Executive Summary
Germany's G-BA, the institute in charge of the country's early benefit assessment process, has given Eisai's breast cancer drug Halaven (eribulin) a positive outcome, despite the drug's lukewarm reception by IQWiG in an earlier stage of the assessment.